Home LiteratureArticle Details
PMID: 8485267 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Two-week eradication regimen for metronidazole-resistant Helicobacter pylori.

Alimentary pharmacology & therapeutics ·Vol. 7 ·No. 2 ·1993-04-00 ·Pages 149-53

Logan RP, Gummett PA, Misiewicz JJ, Karim QN, Walker MM, Baron JH

Abstract

At present there is no generally accepted treatment regimen for eradicating metronidazole-resistant Helicobacter pylori. This study determines the eradication rate after treatment with 40 mg omeprazole o.m. and 500 mg amoxycillin q.d.s. for 14 days, with 120 mg tripotassium dicitrato bismuthate q.d.s. for the first week (Days 1-7) and 750 mg ciprofloxacin b.d. for the second week (Days 8-14). Thirty patients (16 male, mean age 45 years, range 16-80 years) with duodenal ulcers (n = 18) or non-ulcer dyspepsia (n = 2) and metronidazole-resistant H. pylori detected by histology, culture, in vitro sensitivity tests and a positive 13C-urea breath test entered the study. Follow-up was by 13C-urea breath test at the end of treatment and at 1, 3, 6, and 12 months. Eradication was defined as a negative 13C-urea breath test at least 1 month after finishing treatment. H. pylori was successfully eradicated in 21/30 (71%) patients (median follow-up 10.2 months, range 4-12 months). A pre-treatment ciprofloxacin-resistant strain was isolated in 1/9 patients in whom eradication failed. Of 30 patients 29 completed the 2-week regimen; one patient experienced dizziness after 3 days of treatment. The most common side-effect was increased stool frequency (n = 6). This 2-week treatment regimen for metronidazole-resistant H. pylori is well tolerated and achieves an eradication rate of 70%.

MeSH Terms
Adolescent Adult Aged Amoxicillin/administration & dosage,therapeutic use Anti-Ulcer Agents/administration & dosage,therapeutic use Breath Tests Ciprofloxacin/administration & dosage,therapeutic use Drug Resistance, Microbial Drug Therapy, Combination/administration & dosage,therapeutic use Endoscopy, Gastrointestinal Female Gastrointestinal Diseases/diagnosis,drug therapy,microbiology Helicobacter Infections/diagnosis,drug therapy Helicobacter pylori/drug effects Humans Male Metronidazole/pharmacology Middle Aged Omeprazole/administration & dosage,therapeutic use Organometallic Compounds/administration & dosage,therapeutic use
Chemicals
Anti-Ulcer Agents Organometallic Compounds Metronidazole Ciprofloxacin Amoxicillin bismuth tripotassium dicitrate Omeprazole
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Logan R P
Department of Gastroenterology and Nutrition, Central Middlesex Hospital, London, UK.
Gummett P A
Misiewicz J J
Karim Q N
Walker M M
Baron J H
Article Info
Journal
Alimentary pharmacology & therapeutics
Abbr.
Aliment Pharmacol Ther
ISSN
0269-2813
Published
1993-04-00
Pages
149-53
Language
English
Region
England
NLM ID
8707234
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]